Melanoma Survival Rates: Statistics by Stage, Type, and What They Mean

Key Takeaways

• The overall 5-year relative survival rate for melanoma is approximately 94%, reflecting the fact that most cases are diagnosed at an early, localized stage.

• For localized melanoma (confined to the skin), the 5-year relative survival rate is approximately 99%.

• For Stage IV metastatic melanoma, outcomes have transformed: the 5-year survival rate has risen from roughly 5–10% before 2011 to approximately 35% or more with modern immunotherapy and BRAF mutation-targeted therapy.

• Breslow thickness remains one of the strongest individual prognostic factors for early-stage melanoma.

• Survival statistics describe populations, not individuals. Your prognosis is shaped by many factors that statistics cannot fully capture, including treatment, molecular features, and how your body responds.

• If you are looking for genuine reasons for optimism, the melanoma treatment story over the past 15 years is one of the most remarkable in oncology.

Melanoma Survival Rates at a Glance

The overall 5-year relative survival rate for melanoma is approximately 94%, according to SEER (Surveillance, Epidemiology, and End Results) data from the National Cancer Institute. For localized melanoma, disease confined to the original skin site, the 5-year survival rate approaches 99%. For regional disease (spread to nearby lymph nodes), it is approximately 71%. For distant (Stage IV, metastatic) disease, the 5-year rate has climbed to approximately 35% with modern treatment, a remarkable increase from under 10% before 2011. The trajectory of outcomes for advanced melanoma represents one of the most encouraging stories in cancer medicine.

Survival Rates by Stage

The following table presents 5-year relative survival rates for melanoma based on SEER data. These figures reflect the proportion of people with melanoma who are alive 5 years after diagnosis relative to the general population, and are sourced from the NCI’s SEER database (seer.cancer.gov).

For more granular substage data (Stages IA through IIID and Stage IV M subcategories), survival rates vary considerably within the “regional” and “distant” categories. Substage IIA carries a roughly 82% 5-year survival rate; Stage IIC is closer to 53%. Within Stage III, IIIA approaches 78% while IIID is closer to 32%. These numbers are population-level estimates from historical data sets and do not fully reflect the most recent treatment advances.

It is also worth noting: SEER data lags by several years. Survival rates in the “distant” category are actively improving as more patients receive current-generation immunotherapy, and figures published in the coming years will likely reflect further improvement.

How Treatment Has Changed Survival for Advanced Melanoma

The survival statistics for advanced melanoma tell one of the most meaningful stories in modern oncology, and understanding that story provides real context for what a Stage III or Stage IV diagnosis means today versus a decade ago.

Before 2011, the standard treatment for metastatic melanoma was chemotherapy with dacarbazine. Median overall survival was approximately 7–8 months. The 5-year survival rate was in the range of 5–10%. Long-term survivors were extraordinarily rare.

In 2011, ipilimumab (Yervoy), a checkpoint inhibitor targeting CTLA-4, became the first drug in decades to improve overall survival in metastatic melanoma in a randomized trial. The same year, vemurafenib, a BRAF inhibitor, demonstrated rapid and significant responses in patients with BRAF mutation-positive tumors.

Pembrolizumab and nivolumab (PD-1 checkpoint inhibitors) followed, producing higher response rates and more durable remissions than ipilimumab alone. The combination of nivolumab plus ipilimumab, studied in the CheckMate 067 trial, showed a 5-year overall survival rate of approximately 52%, an extraordinary result compared to the pre-immunotherapy era.

Long-term follow-up data from the CheckMate 067 trial (7-year survival data published in 2022) showed that benefit continued to deepen over time: approximately 49% of patients who received the combination were alive at 7 years, a figure that would have been almost unimaginable before 2011. The KEYNOTE-006 trial showed similar long-term durability for pembrolizumab monotherapy, with a 5-year overall survival rate of approximately 43%.

For patients with BRAF-mutated tumors, long-term data from the COMBI-d trial showed that dabrafenib plus trametinib produced a 5-year overall survival rate of approximately 34% in metastatic disease, with a tail of long-term survivors suggesting durable benefit for a proportion of patients.

These results do not mean that every patient with Stage IV melanoma achieves long-term remission, far from it. But they mean that long-term survival is a realistic outcome for a meaningful proportion of patients, and that the starting assumption for advanced melanoma treatment today is fundamentally different from what it was before 2011.

How Breslow Thickness Affects Prognosis

Breslow thickness: the depth of the melanoma tumor measured in millimeters from the skin surface, is one of the single most important prognostic factors for localized melanoma.

The relationship is straightforward: thinner melanomas have a better prognosis.

• Tumors ≤ 1.0 mm (T1): 5-year survival rates in the range of 97–99%

• Tumors 1.01–2.0 mm (T2): approximately 94%

• Tumors 2.01–4.0 mm (T3): approximately 84%

• Tumors > 4.0 mm (T4): approximately 67–78%, varying by ulceration status

These figures apply to localized disease without lymph node involvement. Breslow thickness influences staging, the recommendation for sentinel lymph node biopsy, and the discussion of adjuvant therapy for higher-risk tumors.

The fact that thin melanomas are nearly universally curable with surgery is the strongest argument for regular skin self-examination and routine dermatology visits. A melanoma caught at 0.5 mm has a near-certain chance of cure; the same melanoma caught two years later may be 4 mm thick with very different implications.

Other Factors That Affect Individual Prognosis

While Breslow thickness is the dominant factor in early-stage melanoma, several additional variables shape prognosis:

Ulceration. The presence of ulceration: breakdown of the skin surface over the tumor, is a sign of biological aggressiveness and independently worsens prognosis at every stage. It shifts patients to a higher substage (for example, from Stage IIA to IIB for the same Breslow thickness), reflecting its prognostic significance.

Mitotic rate. The number of actively dividing cells per square millimeter of tumor tissue is a marker of how rapidly the cancer is growing. A higher mitotic rate is associated with worse outcomes in thin melanomas and influences staging decisions.

Lymph node status. Whether and how extensively the cancer has spread to regional lymph nodes is the critical distinction between Stage II and Stage III. The number of involved nodes, whether the involvement is microscopic or clinically detectable, and the presence of in-transit or satellite metastases all affect prognosis within Stage III.

Site of metastasis. In Stage IV disease, where the cancer has spread matters. Skin, subcutaneous tissue, and distant lymph node involvement (M1a) carries a more favorable prognosis than visceral organ spread. Brain metastases (M1d) historically carried the worst prognosis within Stage IV, though modern systemic therapies and stereotactic radiosurgery have improved outcomes here as well.

LDH (lactate dehydrogenase). Elevated serum LDH in Stage IV melanoma is a marker of tumor burden and metabolic activity and is incorporated into staging. It has historically been one of the strongest independent predictors of poor outcomes in metastatic disease.

Treatment response. Patients who achieve a complete response (no detectable disease) on immunotherapy tend to have significantly better long-term outcomes than those with partial responses. Response to treatment is, in a real sense, one of the most important prognostic factors.

Statistics describe populations, not individuals. Two people with identical stages and Breslow depths can have very different outcomes based on molecular features, immune system characteristics, treatment access, and factors that are not fully captured in population-level data. Your oncologist, who knows your complete picture, is your best source of individualized prognostic information.

How to Understand Survival Statistics

When you read that the 5-year survival rate for Stage IV melanoma is 35%, it is worth understanding what that figure does and does not mean.

It describes a population, not a prediction. Survival statistics are aggregated across many patients, many treatment eras, many disease subtypes, and many individual circumstances. They tell you how a group fared on average, not how you, specifically, will do.

The data is historical. SEER data and trial follow-up data reflect patients treated years ago, with the treatments available at the time. Patients receiving current-generation therapies today will likely have better outcomes than the statistics currently reflect. The 35% figure for distant melanoma will probably be higher in five years.

Responders can do far better than the average. The 35% 5-year figure for Stage IV represents an average across patients who respond strongly, patients who respond modestly, and patients who do not respond. Long-term trial data suggest that patients who achieve deep, durable responses on immunotherapy, a meaningful proportion, can remain disease-free for many years.

Your specific features matter. BRAF mutation status, performance status, LDH level, site of metastasis, and treatment history all influence individual prognosis in ways that the overall statistic does not capture.

Use survival statistics as context, not as a forecast. The most useful conversation about your prognosis is with your oncologist, who can interpret the numbers in light of your specific situation.

Can Clinical Trials Improve Outcomes?

The dramatic improvement in melanoma survival rates over the past 15 years was built entirely on clinical trial data. Every approved immunotherapy and targeted therapy for melanoma, ipilimumab, pembrolizumab, nivolumab, dabrafenib, trametinib, relatlimab, lifileucel, was studied and validated in trials before becoming standard of care.

For patients today, clinical trials represent the same opportunity: access to the next generation of treatments before they are widely available. This is particularly relevant for patients with Stage IV disease, where the treatment landscape continues to evolve rapidly. Emerging areas of active trial investigation include personalized mRNA cancer vaccines, next-generation TIL therapies, new checkpoint inhibitor combinations, and strategies to overcome resistance to existing treatments.

Participating in a clinical trial does not mean receiving inferior care. In cancer, trials are often designed to test a new approach against the current best standard, and in many cases, the experimental arm turns out to be better. For patients who have progressed on existing treatments, a trial may be the single best available option.

For more information on treatment options and how outcomes are measured, see melanoma stages and melanoma treatment. To explore current trial options, see melanoma clinical trials.

Treatments for advanced melanoma have improved dramatically in recent years, and clinical trials continue to push outcomes further. Search for melanoma trials through North’s trial finder.

Frequently Asked Questions

What is the survival rate for melanoma by stage?

Based on SEER data, the 5-year relative survival rate for melanoma is approximately 99% for localized disease, 71% for regional spread (nearby lymph nodes), and approximately 35% for distant (Stage IV) metastatic disease. The overall rate across all stages is approximately 94%, reflecting that the majority of melanomas are diagnosed at an early stage. Within each broad category, survival varies by substage, Stage IIC has a notably lower survival rate than Stage IIA, and Stage IIIA is significantly more favorable than Stage IIID.

Has melanoma survival improved?

Yes, dramatically, especially for advanced disease. Before 2011, the 5-year survival rate for Stage IV melanoma was approximately 5–10% and median survival was under 9 months. The introduction of ipilimumab in 2011, followed by PD-1 checkpoint inhibitors and BRAF/MEK-targeted therapies, transformed outcomes. Long-term follow-up data from the CheckMate 067 trial showed approximately 49% of patients receiving combination immunotherapy (nivolumab plus ipilimumab) were alive at 7 years. Outcomes for earlier stages have also improved with adjuvant immunotherapy now available for Stage IIB through Stage III.

What is the survival rate for Stage 4 melanoma?

The 5-year relative survival rate for Stage IV (distant) melanoma is approximately 35% according to current SEER data, a figure that reflects patients treated in recent years with modern immunotherapy and targeted therapy. This is a significant improvement from the pre-2011 era when the 5-year rate was approximately 5–10%. Long-term trial data show that patients who achieve deep, durable responses on combination immunotherapy can remain disease-free for many years. Within Stage IV, outcomes vary by M subcategory (M1a through M1d, with brain metastases historically carrying the worst prognosis).

Does Breslow thickness affect survival?

Yes, Breslow thickness is one of the strongest independent prognostic factors for early-stage melanoma. Tumors 1 mm or less in thickness have 5-year survival rates approaching 97–99%. Tumors over 4 mm have 5-year survival rates in the range of 67–78%, depending on other features like ulceration. Breslow thickness directly influences staging, sentinel lymph node biopsy recommendations, and adjuvant therapy decisions. This is why detecting melanoma when it is thin, through regular self-exams and dermatology appointments, has such a direct impact on outcomes.

What factors most influence melanoma prognosis?

For localized melanoma, Breslow thickness and ulceration are the most important factors. For regional disease, lymph node status (number of involved nodes, microscopic vs. macroscopic involvement) is central. For Stage IV, the site of metastasis and LDH level influence both staging and prognosis. Across all stages, treatment response, particularly achieving a complete or deep partial response on immunotherapy, is a powerful predictor of long-term outcomes. BRAF mutation status is critical for determining treatment eligibility and shapes the treatment path, though its impact on overall prognosis is nuanced.

References

1. National Cancer Institute SEER Program. Cancer Stat Facts: Melanoma of the Skin. https://seer.cancer.gov/statfacts/html/melan.html

2. National Cancer Institute. Melanoma Treatment (PDQ), Patient Version. https://cancer.gov/types/skin/patient/melanoma-treatment-pdq

3. American Cancer Society. Survival Rates for Melanoma Skin Cancer. https://www.cancer.org/cancer/types/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html

4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma (CheckMate 067). N Engl J Med. 2019;381(16):1535-1546. https://pubmed.ncbi.nlm.nih.gov/31562797.

5. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results. Lancet Oncol. 2019;20(9):1239-1251. https://pubmed.ncbi.nlm.nih.gov/31345627.

6. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma (COMBI-d/COMBI-v pooled). N Engl J Med. 2019;381(7):626-636. https://pubmed.ncbi.nlm.nih.gov/31166680